Cambridge Healthtech Institute's Fourteenth Annual

Recombinant Protein Therapeutics

( 重组蛋白质疗法 )

Fusion Proteins & Beyond

2018年1月8日 - 9日

 

Cambridge Healthtech Institute's Fourteenth Annual Recombinant Protein Therapeutics conference once again profiles the varying designs of therapeutic fusion proteins in differing stages of development, and investigates the challenges and benefits associated with these promising therapies. By combining modular building blocks that can reach targets not accessible to antibodies, Fusion Protein Therapeutics possess advantages over antibody-based therapies; their customizable functionality translates into lower patient dosing, reduced production costs, and improved product homogeneity. This conference will disclose how these molecules are being engineered to form more efficacious therapeutics that offer specificity with enhanced stability and longer half-life. Case studies from international experts will be presented covering R&D through clinical data.

Preliminary Agenda


Therapeutic Success with Fusion Proteins

KEYNOTE PRESENTATION:
Fusion Proteins: An Introduction to the Field and Selected Case Studies from Roche’s Research and Early-Development Pipeline

Stefan Weigand, Ph.D., Head, Large Molecule Research, Roche Innovation Center Basel, Roche Pharma Research & Early Development (pRED)


Making Proteins "Druggable": Fc Fusion Proteins as a Therapeutic Class

Steven Chamow, Ph.D., Principal, Chamow & Associates, Inc.

Design, Structure and Manufacturability: Lessons Learnt from Fusion Proteins

Stefan R. Schmidt, Ph.D., M.B.A., CSO, Development and Innovation, Rentschler Biotechnology


Conquering Disease

Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and CCR5 Antagonist Maraviroc in Primary Cells: Implications for Effective Prevention and Treatment

Olga S. Latinovic, Ph.D., Assistant Professor, Institute of Human Virology, University of Maryland School of Medicine

HERA: Engineering Next Generation TNFR-SF Agonists for Cancer Immunotherapy

Oliver Hill, Ph.D., Vice President, Molecular Biology/Protein Engineering, Apogenix AG

Improving Enzyme-Based Therapy of Acute Lymphoblastic Leukemia: Molecular Design of Human L-Asparaginases

Manfred Konrad, Ph.D., Research Director, Enzyme Biochemistry, Max Planck Institute for Biophysical Chemistry


Breakthrough Engineering

Turning Affibody Molecules into Efficient Peptide Binders by Dimerization

John Lofblom, Ph.D., Associate Professor, Protein Technology, Biotechnology, KTH Royal Institute of Technology

Veltis® Engineered Albumins and their Potential for Improved Therapeutic Performance

Helen Rawsthorne, Ph.D., Senior Research Scientist, Molecular Biology and Fermentation, Albumedix


Generating Ion Channel Blocking Antibodies by Fusing Cysteine-Knot Miniproteins into Peripheral CDR Loops

John McCafferty, Ph.D., CEO, Antibody Engineering, IONTAS, Ltd.

Deciphering the Root-Causes for Atypical PK of mAbs and Complex Biologics by Protein Engineering

Thomas Kraft, Ph.D., Postdoctoral Scientist, Large Molecule Research, Roche Diagnostics GmbH


* 活动内容有可能不事先告知作更动及调整。